Biogen pays Elan $3.25 billion to take over MS drug

DUBLIN (Reuters) - Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news